How have PXSLY shares performed in 2024?

Pharmaxis' stock was trading at $0.88 on January 1st, 2024. Since then, PXSLY shares have increased by 0.0% and is now trading at $0.88. View the best growth stocks for 2024 here .

How do I buy shares of Pharmaxis?

Shares of PXSLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:PXSLY

Pharmaxis (PXSLY) Stock Price, News & Analysis

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Free PXSLY Stock Alerts

$0.88

0.00 (0.00%)

(As of 06/8/2021)

Compare

Today's Range: $0.88
▼
$0.88
50-Day Range: $0.88
▼
$0.88
52-Week Range: $0.62
▼
$1.47

Volume: N/A
Average Volume: 1,000 shs
Market Capitalization: $26.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Pharmaxis alerts:

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About Pharmaxis Stock (OTCMKTS:PXSLY)

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

PXSLY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PXSLY Stock News Headlines

October 5, 2021 | feeds.benzinga.com

Proactive news headlines including Aurumin, PolarX, Valor Resources and Hartshead Resources

See More Headlines

Receive PXSLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:PXSLY
CUSIP: N/A
CIK: 1301357
Web: www.pharmaxis.com.au
Phone: 61-2-9454-7200
Fax: N/A
Employees: 69
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 2.82
Current Ratio: 3.31
Quick Ratio: 2.92

Sales & Book Value

Annual Sales: $8.75 million
Price / Sales: 3.03
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.04 per share
Price / Book: 22.00

Miscellaneous

Outstanding Shares: 30,150,000
Free Float: N/A
Market Cap: $26.53 million
Optionable: Not Optionable
Beta: 1.22

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Gary Jonathan Phillips (Age 60)
CEO, MD & Director
Comp: $375.28k
Mr. David Morris McGarvey BA (Age 65)
CA, CPA, CFO & Company Sec.
Comp: $309.66k
Dr. Wolfgang G. Jarolimek Ph.D. (Age 57)
B.Sc. Ph.D., Head of Drug Discovery
Comp: $304.82k
Ms. Kristen Morgan B.Sc. (Age 49)
BSc, PGDipBusAdmin, MMedSc, Alliance Management - Head of Medical & Regulatory Affairs
Comp: $168.68k
Dr. Brett Charlton Ph.D. (Age 65)
MBBS Ph.D., Medical Director
Comp: $304.7k
Mr. Cameron David Billingsley (Age 44)
Gen. Counsel
Dr. Dieter Hamprecht
Head of Chemistry for Drug Discovery

Key Competitors

View All Competitors

PXSLY Stock Analysis - Frequently Asked Questions

How have PXSLY shares performed in 2024?: Pharmaxis' stock was trading at $0.88 on January 1st, 2024. Since then, PXSLY shares have increased by 0.0% and is now trading at $0.88.
View the best growth stocks for 2024 here.
How do I buy shares of Pharmaxis?: Shares of PXSLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PXSLY) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial